

Personal Info

☎ 0742584838

✉ ioana-maria.suciu@umft.ro

📍 6 Călinei Street, Alba Iulia,
510185, România

Nationality
Romanian

Driving License
B

Date of birth
15.08.1997

Skills

☐ Research

Languages

☐ English

☐ French

Ioana-Maria Suciu

Doctor

Work Experience

**Cardiology Resident, Institute of Cardiovascular Diseases,
Timisoara, Romania**
January 2022 - Present

Cardiology Resident, Centre Hospitalier de Béziers, France
June 2024 - May 2025

**COVID-19 Support Volunteer – Infectious Diseases Department,
Ward 3, Emergency County Hospital Reșița, Romania, Reșița**
December 2020 - January 2021

**Vice President of Communications, Romanian Society of Surgery
Students – Timișoara Branch**
September 2018 - September 2019

Coordinated sub-departments:

- Public Relations
- Fundraising
- Human Resources
- Social Activities

**VADA Volunteer (Volunteer Program for Academic Development),
Department of Physiology, University of Medicine and Pharmacy
Victor Babeș, Timișoara, Romania**
September 2017 - September 2018

Provided tutoring for 1st and 2nd year medical students in:

- Cardiovascular physiology
- Respiratory physiology
- Renal physiology
- Nervous system physiology
- Endocrine physiology

Education

**PhD Student, University of Medicine and Pharmacy Victor Babeș,
Timișoara, Romania**
2022 - Present

**MD, University of Medicine and Pharmacy Victor Babeș, Timișoara,
Romania (General Medicine)**
2015 - 2021

**High School Diploma (Baccalaureate), "Horea, Cloșca și Crișan"
National College, Alba Iulia, Romania (Philology – English Bilingual
Program)**
2011 - 2015

List of Published Articles

1. Suciu, I.-M.; Greluș, A.; Cozlac, A.-R.; Suciu, B.-S.; Stoica, S.; Luca, S.; Luca, C.-T.; Gaiță, D.-I. Fournier's Gangrene as an Adverse Event Following Treatment with Sodium Glucose Cotransporter 2 Inhibitors. *Medicina* 2024, 60, 837.
<https://doi.org/10.3390/medicina60050837>
2. Suciu, I.M.; Luca, S.A.; Crișan, S.; Cozlac, A.-R.; Stoica, S.; Luca, C.T.; Timar, B.; Gaita, D. Do SGLT2 Inhibitors Improve Cardiovascular Outcomes After Acute Coronary Syndrome Regardless of Diabetes? A Systematic Review and Meta-Analysis. *Medicina* 2025, 61, 1866.
<https://doi.org/10.3390/medicina61101866>
3. Patterns in Prescribing and Predictors of SGLT2 Inhibitor Administration in Patients with Heart Failure and Acute Myocardial Infarction: A Real-World Retrospective Cohort Study
4. Suciu, I.M.; Muntean, C.; Gaiță, L.; Mateoc-Sîrb, T.; Vlad, D.C.; Timar, B.; Gaiță, D. Disentangling Uric Acid and Renal Pathways in SGLT2 Inhibitor Effects After Acute Myocardial Infarction: A Retrospective Mediation Analysis. *Biomedicines* 2026, 14, 842.
<https://doi.org/10.3390/biomedicines14040842>
5. Mateoc, T.; Suciu, I.-M.; Gaiță, D.; Minodora, A.; Popescu, R.; Vlad, T.; Flangea, C.; Muntean, C.; Vlad, D.-C. Early SGLT2 Inhibitor Therapy in Acute Coronary Syndrome: Mitigating Adverse Remodeling in High-Risk Phenotypes—A Real-World Study. *Medicina* 2026, 62, 205. <https://doi.org/10.3390/medicina62010205>
6. Mateoc-Sîrb, T.; Suciu, I.-M.; Gaiță, D.; Minodora, A.; Popescu, R.; Vlad, T.; Muntean, C.; Vlad, D.-C. Guideline-Directed Medical Therapy Intensity, Ventricular Remodeling, and Clinical Outcomes After Acute Myocardial Infarction: A Single-Center Real-World Retrospective Cohort Study. *Biomedicines* 2026, 14, 1067.
<https://doi.org/10.3390/biomedicines14051067>